

Supplementary Table 2. Baseline patient characteristics by availability of sTILs data			
Characteristic – N (%)		All patients (N=474)	Available sTILs data (N=388)
Age at diagnosis, years – median (range)		52 (29-80)	53 (29-80)
Race	White	425 (90%)	351 (91%)
	Black	39 (8%)	28 (7%)
	Other	9 (2%)	8 (2%)
Ethnicity ^a	Non-Hispanic	402 (85%)	324 (84%)
	Hispanic	69 (15%)	62 (16%)
Menopausal status ^b	Pre	221 (47%)	175 (45%)
	Post	251 (53%)	212 (55%)
Histological grade ^c	1-2	113 (25%)	88 (24%)
	3	341 (75%)	283 (76%)
T stage	1	85 (18%)	66 (17%)
	2	271 (57%)	229 (59%)
	3	76 (16%)	56 (14%)
	4	42 (9%)	37 (10%)
Lymph node status ^d	Negative	261 (55%)	214 (56%)
	Positive	210 (45%)	171 (44%)
TNM stage	I	62 (13%)	61 (13%)
	II	299 (62%)	293 (62%)
	III	119 (25%)	119 (25%)
ER/PgR	ER and PgR <1%	453 (96%)	373 (96%)
	ER and/or PgR 1-10%	21 (4%)	15 (4%)
Germline <i>BRCA1/2</i> mutation	Yes	63 (13%)	47 (12%)
	No	371 (78%)	310 (80%)
	Unknown	40 (8%)	31 (8%)

^aRace is not known for n=1 patient

^bEthnicity is not known for n=3 patients

^cMenopausal status is not known for n=2 patients

^dHistological grade is not available for n=20 patients

^eLymph node status is not available for n=3 patients

Abbreviations: ER, estrogen receptor; PgR, progesterone receptor; sTILs, stromal tumor-infiltrating lymphocytes